Fast Track Demand Leverage DefenCath’s FDA Fast Track and QIDP designations to position for expedited market access discussions, payer dialogues, and potential collaboration opportunities with hospital systems and dialysis centers seeking high-impact infection prevention solutions.

Strong Q2 Revenue capitalize on robust Q2 financials with revenue around 101.9 million and adjusted EBITDA of 58.7 million to engage investors, partners, and potential customers showing financial stability and growth trajectory that can support larger manufacturing or supply agreements for DefenCath and Neutrolin.

Catheter Infection Solution Target dialysis networks, nephrology groups, and hospital procurement teams with DefenCath and Neutrolin as anti-infective catheter solutions to reduce bloodstream infection risks, potential readmission costs, and overall patient morbidity among chronic hemodialysis patients.

Commercial Leadership With a past chief commercial officer departure, emphasize continuity of market strategy and opportunities to onboard experienced partnerships, distributors, or regional sales reps to sustain and scale DefenCath launches across current and new markets.

Growth & Expansion Align with opportunities around Neutrolin development and adjacent prophylactic infection-control products, exploring co-development or licensing deals, manufacturing capacity expansions, and strategic collaborations to broaden the product portfolio and geographic reach.